Details for Patent: 10,973,769
✉ Email this page to a colleague
Which drugs does patent 10,973,769 protect, and when does it expire?
Patent 10,973,769 protects CREXONT and is included in one NDA.
This patent has twenty-seven patent family members in twelve countries.
Summary for Patent: 10,973,769
| Title: | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| Abstract: | The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and a method of using the controlled release oral solid formulation to treat Parkinson's disease or primary parkinsonism. |
| Inventor(s): | Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta |
| Assignee: | Impax Laboratories LLC |
| Application Number: | US16/864,323 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,973,769 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Device; Dosage form; |
Drugs Protected by US Patent 10,973,769
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-001 | Aug 7, 2024 | RX | Yes | No | 10,973,769 | ⤷ Start Trial | Y | TREATMENT OF PARKINSON'S DISEASE | ⤷ Start Trial | |||
| Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-002 | Aug 7, 2024 | RX | Yes | No | 10,973,769 | ⤷ Start Trial | Y | TREATMENT OF PARKINSON'S DISEASE | ⤷ Start Trial | |||
| Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-003 | Aug 7, 2024 | RX | Yes | No | 10,973,769 | ⤷ Start Trial | Y | TREATMENT OF PARKINSON'S DISEASE | ⤷ Start Trial | |||
| Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-004 | Aug 7, 2024 | RX | Yes | Yes | 10,973,769 | ⤷ Start Trial | Y | TREATMENT OF PARKINSON'S DISEASE | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,973,769
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014332024 | ⤷ Start Trial | |||
| Australia | 2019284060 | ⤷ Start Trial | |||
| Australia | 2021282393 | ⤷ Start Trial | |||
| Canada | 2926082 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
